ADVANCED MICROBIOTA DRUG DEVELOPMENT PLATFORM

We are harnessing the complete microbiota ecosystem to develop novel biological drugs and microbiome therapies for various diseases.

Complete Microbiota Ecosystem Products

Microviable Therapeutics’ lead product represent the complete gut microbiota ecosystem with high diversity and full functionality to be harnessed as a biological drug. This unique complete microbiota ecosystem product is a non-propagated, donor-derived, high-diversity and high-richness product generated with our proprietary technology obtaining human purified microbiota (HPM®) in viable conditions.

Our lead candidate MVT-201, is an orally administered capsule generated under cGMP conditions representing the complete gut microbiota of a clinically validated healthy donor and will get into the clinical trials in 2023 for undisclosed targets.

Microbiota Therapies

Our capability to obtain donor-derived human purified microbiota enable us to perform microbiota therapies as personalized medicine.

The gut microbiota of a specific individual can be purified and use for autologous or heterologous applications, either in native conditions or rationally modified for the depletion or enrichment of the desired bacterial populations.

These microbiome therapies are being co-developed in partnership with Inmunomet Intolerancias y Disbiosis

Microbiota Therapies

Our capability to obtain donor-derived human purified microbiota enable us to perform microbiota therapies as personalized medicine.

The gut microbiota of a specific individual can be purified and use for autologous or heterologous applications, either in native conditions or rationally modified for the depletion or enrichment of the desired bacterial populations.

These microbiome therapies are being co-developed in partnership with Inmunomet Intolerancias y Disbiosis

PharmaBiota® Platform

Our Advance Microbiota Drug Development Platform enables the generation of a novel category of biotherapeutic products based on commensal bacteria developing personalized drugs for unmet clinical needs.

Our large and diverse proprietary bacterial culture collection together with our bioinformatics platform enable the discovery of novel microbiota-derived biological drugs, tailored with our in house characterization pipeline and cGMP production.

Patent No. Title Applicant Issue date
ES201630176 Device for microbiota collection and transport in anaerobic condition CSIC July 10, 2018
EP19383077 Tools and methods to detect and isolate colibactin producing bacteria CSIC Pending
Trade Secret (ref.: 2203) Methods for long-term preservation of gut microbiota in viable conditions CSIC-MVT April 13, 2021
Trade mark PharmaBiota® Microviable Therapeutics December 02, 2022
Trade mark HiPM® – Human Purified Microbiota Microviable Therapeutics June 08, 2022
Trade mark GutAlive® Microviable Therapeutics January 23, 2018
Trade mark Microviable Therapeutics® Microviable Therapeutics April 26, 2017

Patent No.: ES201630176

Title: Device for microbiota collection and transport in anaerobic condition

Applicant: CSIC

Issue date: July 10, 2018

Patent No.: EP19383077

Title: Tools and methods to detect and isolate colibactin producing bacteria

Applicant: CSIC

Issue date: Pending

Patent No.: Trade Secret (ref.: 2203)

Title: Methods for long-term preservation of gut microbiota in viable conditions

Applicant:CSIC-MVT

Issue date: April 13, 2021

Patent No.: Trade mark

Title: PharmaBiota®

Applicant: Microviable Therapeutics

Issue date: December 02, 2022

Patent No.: Trade mark

Title: HiPM® – Human Purified Microbiota

Applicant: Microviable Therapeutics

Issue date: June 08, 2022

Patent No.: Trade mark

Title: GutAlive®

Applicant: Microviable Therapeutics

Issue date: January 23, 2018

Patent No.: Trade mark

Title: Microviable Therapeutics®

Applicant: Microviable Therapeutics

Issue date: April 26, 2017

* All the disclosed IP has been licensed with exclusive rights to Microviable Therapeutics SL.

MICROVIABLE THERAPEUTICS

CONTACT US